ACR/ARP members share why they support the ACR’s nonpartisan political action committee and see it as an investment in the future of rheumatology.
Search results for: liver
Secukinumab Effective Across the Spectrum of Psoriatic Arthritis
A posthoc analysis confirms patients with active psoriatic arthritis (PsA) taking secukinumab experience improvement in all signs and symptoms of PsA as measured by the GRAPPA-OMERACT disease activity core domains.
An Analysis of the Jobs Listed in the ACR’s CareerConnection Portal
Rheumatologists play a critical role in healthcare delivery, especially with an aging U.S. population. Despite this, a workforce shortage exists—one that is projected to worsen.1,2 The ACR CareerConnection service is free to job seekers searching for opportunities in the field of rheumatology.3 This study examines currently available rheumatology employment opportunities across the U.S. The ACR…
Tips for Balancing Medication Treatment & Risk in Elderly Patients
ACR CONVERGENCE 2020—With the inevitable decline in organ function that comes with age, and the likelihood that older patients (i.e., generally defined as older than 60 or 70, depending on the study) are on more than one medication due to multiple comorbidities, therapeutic drug treatment for older patients requires persistent vigilance and know-how, two experts…
Micromotors Promising for Rheumatoid Arthritis Therapy
NEW YORK (Reuters Health)—Magnesium-based micromotors showed promise as a delivery system for hydrogen therapy to inflamed joints in an experimental model of rheumatoid arthritis, researchers say. Hydrogen gas has been shown to neutralize overproduction of reactive oxygen species (ROS), which can degrade cartilage and bone and activate inflammatory cytokines, according to Dr. Yingfeng Tu of…
Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss
NEW YORK (Reuters Health)—Long-term glucocorticoid users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab vs. oral alendronate, a small clinical trial shows. The drug also proved superior at lowering bone-turnover markers at 12 months, researchers in Hong Kong report in Bone.1 “Denosumab may be considered as an alternative first-line…
Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks
In Canada, a subcutaneous formulation of CT-P13, which is biosimilar to infliximab, was approved to treat rheumatoid arthritis.
Wisconsin Rheumatology Association Targets Rural Workforce Shortages, Advocacy Needs
Now in its 16th year, the Wisconsin Rheumatology Association engages and supports rheumatology professionals through advocacy sessions, annual meetings and continuing medical education-accredited events.
Modern Treatment Tied to Low Disease Activity in Pregnant RA Patients
(Reuters Health)—Many pregnant women with rheumatoid arthritis (RA) may achieve low disease activity in the third trimester with a modern treatment regimen that includes anti-tumor necrosis factor (TNF) medications, a recent study suggests. Researchers examined data on 309 patients with RA who were pregnant or trying to conceive and who were treated with modern treat-to-target…
The ACR Addresses Vaccine Challenges
An ACR COVID-19 Vaccine task force examined vaccine data and literature to evaluate COVID-19 vaccine safety, efficacy and interaction with medications for patients with rheumatic and musculoskeletal diseases, and to craft a living guidance document for members.
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 127
- Next Page »